

July 14, 2023

Kidswell Bio Corporation

Code: 4584 (TSE Growth Market)

Shinya Kurebayashi, President & CEO

Correction of the press release on July 10, 2023

Tokyo, July 14, 2023 – Kidswell Bio Corporation has revised the working capital financing for stable supply for GBS-007, which was previously announced on July 10, 2023 as follows.

1. Reasons for the revision

There was an error in the first revision date of the exercise price of 18th series of stock acquisition rights for securing the working capital of biosimilar business.

2. Correction

〈Before correction〉

The exercise price of the 18th stock acquisition rights shall be determined by August 3, 2023 as the first revision date, (the rest is omitted.)

〈After correction〉

The exercise price of the 18th stock acquisition rights shall be determined by July 27, 2023 as the first revision date, (the rest is omitted.)

*Corrections are underlined.

About Kidswell Bio Corporation (KWB)

Kidswell Bio Corporation will challenge pediatric disease as a new field, in addition to intractable and rare diseases on which KWB has also been focusing for R&D. We would like to contribute to children who have hopes and dreams for their bright future. Furthermore, with our biotech expertise and children's potential vital force such as SHED, we envision creating new pharmaceuticals and therapeutics for all people under "Kids Well, All Well."

Contact:

Kidswell Bio Corporation

Tel: +81-3-6222-9547 Mail: info@kidswellbio.com